These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 1642686

  • 21. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin.
    Misaizu T, Matsuki S, Strickland TW, Takeuchi M, Kobata A, Takasaki S.
    Blood; 1995 Dec 01; 86(11):4097-104. PubMed ID: 7492766
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice.
    Ferraiolo BL, Moore JA, Crase D, Gribling P, Wilking H, Baughman RA.
    Drug Metab Dispos; 1988 Dec 01; 16(2):270-5. PubMed ID: 2898346
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics and haematological parameters of recombinant human erythropoietin after subcutaneous administrations in horses.
    Souillard A, Audran M, Bressolle F, Jaussaud P, Gareau R.
    Biopharm Drug Dispos; 1996 Dec 01; 17(9):805-15. PubMed ID: 8968532
    [Abstract] [Full Text] [Related]

  • 24. Plasma disappearance and organ distribution of recombinant human tumor necrosis factor-alpha in rats.
    Pang XP, Hershman JM, Pekary AE.
    Lymphokine Cytokine Res; 1991 Aug 01; 10(4):301-6. PubMed ID: 1932374
    [Abstract] [Full Text] [Related]

  • 25. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG, Fischer ER, Harris DC.
    Clin Nephrol; 1993 Nov 01; 40(5):277-80. PubMed ID: 8281716
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin.
    Salmonson T.
    Scand J Urol Nephrol Suppl; 1990 Nov 01; 129():1-66. PubMed ID: 2255869
    [Abstract] [Full Text] [Related]

  • 27. Thrombopoietic factor enhances murine megakaryopoiesis induced by recombinant erythropoietin.
    Nagasawa T, Satoh K, Abe T.
    Int J Hematol; 1991 Apr 01; 54(2):159-64. PubMed ID: 1747449
    [Abstract] [Full Text] [Related]

  • 28. The in vivo metabolism of recombinant human erythropoietin in the rat.
    Spivak JL, Hogans BB.
    Blood; 1989 Jan 01; 73(1):90-9. PubMed ID: 2462945
    [Abstract] [Full Text] [Related]

  • 29. The effect of human recombinant erythropoietin on iron absorption and hepatic iron in a rat model.
    Adams PC, Chau LA, Lin E, Muirhead N.
    Clin Invest Med; 1991 Oct 01; 14(5):432-6. PubMed ID: 1742921
    [Abstract] [Full Text] [Related]

  • 30. Sexual dimorphism of erythropoietin-degrading activity in mouse submaxillary gland extracts.
    Tam RC, Bedwell J, Cotes PM, Reed PJ.
    Exp Hematol; 1989 Feb 01; 17(2):160-3. PubMed ID: 2912738
    [Abstract] [Full Text] [Related]

  • 31. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1996 Aug 01; 383():1-370. PubMed ID: 12692653
    [Abstract] [Full Text] [Related]

  • 32. Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis.
    Mitsuma W, Ito M, Kodama M, Fuse K, Okamura K, Minagawa S, Kato K, Hanawa H, Toba K, Nakazawa M, Aizawa Y.
    Biochem Biophys Res Commun; 2006 Jun 09; 344(3):987-94. PubMed ID: 16631620
    [Abstract] [Full Text] [Related]

  • 33. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
    Vannucchi AM, Bosi A, Linari S, Guidi S, Longo G, Lombardini L, Mariani MP, Saccardi R, Laszlo D, Rossi Ferrini P.
    Haematologica; 1997 Jun 09; 82(1):53-6. PubMed ID: 9107083
    [Abstract] [Full Text] [Related]

  • 34. The erythropoietic effects of interleukin 6 and erythropoietin in vivo.
    Ulich TR, del Castillo J, Yin SM, Egrie JC.
    Exp Hematol; 1991 Jan 09; 19(1):29-34. PubMed ID: 1989892
    [Abstract] [Full Text] [Related]

  • 35. Recombinant human erythropoietin (rh-Epo) administration to normal marrow donors.
    York A, Clift RA, Sanders JE, Buckner CD.
    Bone Marrow Transplant; 1992 Nov 09; 10(5):415-7. PubMed ID: 1464002
    [Abstract] [Full Text] [Related]

  • 36. Expression and characterization of erythropoietin receptors on normal human bone marrow cells.
    Hoshino S, Teramura M, Takahashi M, Motoji T, Oshimi K, Ueda M, Mizoguchi H.
    Int J Cell Cloning; 1989 May 09; 7(3):156-67. PubMed ID: 2543713
    [Abstract] [Full Text] [Related]

  • 37. Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo.
    Kuwabara T, Uchimura T, Takai K, Kobayashi H, Kobayashi S, Sugiyama Y.
    J Pharmacol Exp Ther; 1995 Jun 09; 273(3):1114-22. PubMed ID: 7540687
    [Abstract] [Full Text] [Related]

  • 38. Erythropoietin response and route of administration.
    Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK.
    Clin Nephrol; 1994 May 09; 41(5):297-302. PubMed ID: 8050210
    [Abstract] [Full Text] [Related]

  • 39. Distribution of the recombinant coagulation factor 125I-rFVIIa in rats.
    Beeby TL, Chasseaud LF, Taylor T, Thomsen MK.
    Thromb Haemost; 1993 Sep 01; 70(3):465-8. PubMed ID: 8259550
    [Abstract] [Full Text] [Related]

  • 40. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).
    Kirkeby A, Torup L, Bochsen L, Kjalke M, Abel K, Theilgaard-Monch K, Johansson PI, Bjørn SE, Gerwien J, Leist M.
    Thromb Haemost; 2008 Apr 01; 99(4):720-8. PubMed ID: 18392330
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.